Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Karanahan: A Potential New Treatment Option for Human Breast Cancer and Its Validation in a Clinical Setting.
Proskurina AS, Kupina VV, Efremov YR, Dolgova EV, Ruzanova VS, Ritter GS, Potter EA, Kirikovich SS, Levites EV, Ostanin AA, Chernykh ER, Babaeva OG, Sidorov SV, Bogachev SS. Proskurina AS, et al. Among authors: sidorov sv. Breast Cancer (Auckl). 2022 Feb 14;16:11782234211059931. doi: 10.1177/11782234211059931. eCollection 2022. Breast Cancer (Auckl). 2022. PMID: 35185333 Free PMC article.
A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.
Alyamkina EA, Nikolin VP, Popova NA, Dolgova EV, Proskurina AS, Orishchenko KE, Efremov YR, Chernykh ER, Ostanin AA, Sidorov SV, Ponomarenko DM, Zagrebelniy SN, Bogachev SS, Shurdov MA. Alyamkina EA, et al. Among authors: sidorov sv. Genet Vaccines Ther. 2010 Nov 1;8:7. doi: 10.1186/1479-0556-8-7. Genet Vaccines Ther. 2010. PMID: 21040569 Free PMC article.
Effects of human exogenous DNA on production of perforin-containing CD8+ cytotoxic lymphocytes in laboratory setting and clinical practice.
Alyamkina EA, Leplina OY, Ostanin AA, Chernykh ER, Nikolin VP, Popova NA, Proskurina AS, Gvozdeva TS, Dolgova EV, Orishchenko KE, Rogachev VA, Sidorov SV, Varaksin NA, Ryabicheva TG, Bogachev SS, Shurdov MA. Alyamkina EA, et al. Among authors: sidorov sv. Cell Immunol. 2012 Mar-Apr;276(1-2):59-66. doi: 10.1016/j.cellimm.2012.04.004. Epub 2012 Apr 7. Cell Immunol. 2012. PMID: 22578800
Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Zagrebelniy SN, Rogachev VA, Bogachev SS, Shurdov MA. Proskurina AS, et al. Among authors: sidorov sv. BMC Cancer. 2015 Mar 13;15:122. doi: 10.1186/s12885-015-1142-z. BMC Cancer. 2015. PMID: 25886605 Free PMC article. Clinical Trial.
Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Zagrebelniy SN, Rogachev VA, Bogachev SS, Shurdov MA. Proskurina AS, et al. Among authors: sidorov sv. BMC Cancer. 2016 Feb 17;16:117. doi: 10.1186/s12885-016-2163-y. BMC Cancer. 2016. PMID: 26887451 Free PMC article. No abstract available.
Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.
Proskurina AS, Gvozdeva TS, Potter EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Rogachev VA, Shurdov MA, Bogachev SS. Proskurina AS, et al. Among authors: sidorov sv. BMC Cancer. 2016 Aug 18;16:651. doi: 10.1186/s12885-016-2711-5. BMC Cancer. 2016. PMID: 27538465 Free PMC article. Clinical Trial.
Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma.
Kisaretova PE, Kirikovich SS, Ritter GS, Efremov YR, Taranov OS, Dubatolova TD, Proskurina AS, Potter EA, Dolgova EV, Sidorov SV, Ostanin AA, Chernykh ER, Bogachev SS. Kisaretova PE, et al. Among authors: sidorov sv. Anticancer Res. 2020 Feb;40(2):795-805. doi: 10.21873/anticanres.14011. Anticancer Res. 2020. PMID: 32014922
Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model.
Ruzanova V, Proskurina A, Efremov Y, Kirikovich S, Ritter G, Levites E, Dolgova E, Potter E, Babaeva O, Sidorov S, Taranov O, Ostanin A, Chernykh E, Bogachev S. Ruzanova V, et al. Pathol Oncol Res. 2022 May 27;28:1610180. doi: 10.3389/pore.2022.1610180. eCollection 2022. Pathol Oncol Res. 2022. PMID: 35693632 Free PMC article.
Establishment of primary human breast cancer cell lines using "pulsed hypoxia" method and development of metastatic tumor model in immunodeficient mice.
Nushtaeva AA, Karpushina AA, Ermakov MS, Gulyaeva LF, Gerasimov AV, Sidorov SV, Gayner TA, Yunusova AY, Tkachenko AV, Richter VA, Koval OA. Nushtaeva AA, et al. Among authors: sidorov sv. Cancer Cell Int. 2019 Feb 28;19:46. doi: 10.1186/s12935-019-0766-5. eCollection 2019. Cancer Cell Int. 2019. PMID: 30858763 Free PMC article.
34 results